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Abstract: Advancements in the clinical practice of non-small cell lung cancer (NSCLC) are shifting
treatment paradigms towards increasingly personalized approaches. Liquid biopsies using various
circulating analytes provide minimally invasive methods of sampling the molecular content within
tumor cells. Plasma-derived circulating tumor DNA (ctDNA), the tumor-derived component of
cell-free DNA (cfDNA), is the most extensively studied analyte and has a growing list of applications
in the clinical management of NSCLC. As an alternative to tumor genotyping, the assessment of
oncogenic driver alterations by ctDNA has become an accepted companion diagnostic via both
single-gene polymerase chain reactions (PCR) and next-generation sequencing (NGS) for advanced
NSCLC. ctDNA technologies have also shown the ability to detect the emerging mechanisms of
acquired resistance that evolve after targeted therapy. Furthermore, the detection of minimal residual
disease (MRD) by ctDNA for patients with NSCLC after curative-intent treatment may serve as a
prognostic and potentially predictive biomarker for recurrence and response to therapy, respectively.
Finally, ctDNA analysis via mutational, methylation, and/or fragmentation multi-omic profiling
offers the potential for improving early lung cancer detection. In this review, we discuss the role of
ctDNA in each of these capacities, namely, for molecular profiling, treatment response monitoring,
MRD detection, and early cancer detection of NSCLC.
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1. Introduction
Revolutionary developments in ultrasensitive sequencing approaches have led to
the successful implementation of liquid biopsies to inform clinical decisions in patients
with advanced NSCLC [1–4]. Liquid biopsies provide a minimally invasive method of
cancer assessment via the analysis of circulating analytes, such as circulating nucleic
acids (circulating tumor DNA (ctDNA) and cell-free RNA (cfRNA)), circulating tumor
cells (CTCs), microRNAs, extracellular vesicles, tumor-educated platelets, and tumorspecific cell-free DNA methylation. These analytes can be found in several biological fluids,
including plasma, serum, urine, pleural fluid, saliva, and cerebrospinal fluid (CSF) [3,5–11].
The presence of cell-free nucleic acid fragments in the blood was first described by Mandel
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(C) detection of minimal residual disease, and (D) early cancer detection. (A) ctDNA can be readily used to identify cancer-related aberrations (e.g., detection of EGFR L858R) with ultrasensitive
detection, for ease of use when tissue is limited or exhausted, or as a complementary diagnostic
tool with rapid turn-around times. (B) The ease of ctDNA detection by serial blood draws permits
treatment response monitoring of tumor biology evolution, via the detection of potential mechanisms
of acquired resistance (e.g., EGFR T790M on first-generation EGFR TKIs). (C) ctDNA is a powerful
tool for minimal residual disease (MRD) detection after curative-intent multimodal therapy (i.e.,
chemotherapy, radiation, and immunotherapy) in locally advanced NSCLC. ctDNA MRD positivity
can be detected generally prior to radiographic progression to aid in decision making for patient care.
(D) In an effort to improve early cancer detection in high-risk individuals, minimally invasive ctDNA
analysis via mutational, methylation, and/or fragmentation profiles offers promising potential to
complement radiographic screening with low-dose CT chest (LDCT chest).

2. Pre-Analytical Conditions for ctDNA Assessment
ctDNA is a highly sensitive, minimally invasive resource for the qualitative and quantitative molecular profiling of NSCLC. However, the assessment of ctDNA introduces
substantial challenges and drawbacks, including modifiable (e.g., technical considerations)
and non-modifiable variables (e.g., tumor heterogeneity) that impact the sensitivity of
its analysis (Table 1). Here, we aim to highlight key pre-analytical conditions that influence the performance of ctDNA assays, including the integral aspects of venipuncture,
collection tubes and preservatives for cellular stability, and specimen processing time for
successful analysis.
Although no standard collection volume has been established for ctDNA analysis,
given the low concentration of ctDNA in plasma (concentration, 1 to 18 ng per mL), the
collection of large volumes of blood (typically, 10 to 18 mL) are recommended to increase
analytical sensitivity [27,28]. Phlebotomies are to be performed via slow extraction from
the patient to prevent the hemolysis of surrounding leukocytes [29]. Samples can be
directly collected in K2EDTA tubes (i.e., BD Vacutainer® Blood Collection Tubes) if there is
a limited shelf-life for storage (e.g., less than 6 h) prior to the isolation of ctDNA. However,
with K2EDTA collection, if plasma preparation by centrifugation is delayed (e.g., by more
than 24 h from venipuncture), noticeable DNA contamination will be apparent within the
sample from presumed leukocyte lysis, resulting in false elevations in cfDNA content and
poor sample quality [30]. Alternatively, newer formulations of tubes (e.g., Streck cfDNA
BCT® and PAXgene Blood ccfDNA Tubes) containing proprietary preservatives for cellular
integrity are permissible for shipping at ambient temperature, with ctDNA stability of up
to one week from venipuncture [30,31].
Timing, temperature, and sample collection represent a snapshot of important preanalytical conditions that can significantly impact the quality of ctDNA analysis. As
ultra-sensitive techniques become a mainstay of clinical practice for ctDNA analysis, rigorous standardized methods for collection and processing with either guideline-based or
institutional CLIA-based protocols are highly recommended.
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Table 1. ctDNA detection techniques.
Technology

Examples

Assay Personalization

Reported LOD
(% of cfDNA)

Potential Clinical Uses

Limitations

AS-PCR

ARMS [32],
Cobas EGFR mutation test v2
(Roche) [33]

Some Required

~0.1–1

Molecular Profiling

Detects only known mutations or a
small number of variants
concurrently; low sensitivity

dPCR

dPCR [34],
ddPCR [35],
BEAMing [36]

Some Required

~0.01

Molecular Profiling, Treatment
Monitoring, ctDNA MRD

Detects only known mutations or a
small number of variants

Multiplex PCR-based NGS

TAm-Seq [4],
TAm-Seq Enhanced [37],
Safe-SeqS [38],
Natera® [39]

Some Required

~0.01–2.0

Molecular Profiling, Treatment
Monitoring, ctDNA MRD

Detects only known mutations; less
comprehensive than other NGS
methods; incapable of detecting
SCNAs and fusions without assay
personalization

Hybrid captured-based NGS

CAPP-Seq [40,41],
TEC-Seq [42],
Guardant360® [25,43,44],
FoundationOne® Liquid
CDx [26,45]

Not Required

~0.001–0.5

Molecular Profiling, Treatment
Monitoring, ctDNA MRD

Less comprehensive than WGS and
WES

WES

WES [46]

Not Required

~5

Molecular Profiling, ctDNA MRD

Low sensitivity; high cost

WGS

WGS [47,48]

Not Required

~10

Molecular Profiling, ctDNA MRD

Low sensitivity; mostly limited to
SCNA detection; high cost

cfDNA methylation

cfMeDIP-seq [49],
cfMBD-seq [50],
GRAIL Galleri™ [51]

Not Required

Variable

Early Lung Cancer Detection, ctDNA
MRD

Variable/limited sensitivity for
early-stage disease detection

Fragmentomics

DELFI [52]

Not Required

Variable

Early Lung Cancer Detection, ctDNA
MRD

Variable/limited sensitivity for
early-stage disease detection

Combined approaches

CAPP-Seq + GRP [53],
CancerSEEK [54]

Variable

Variable

Early Lung Cancer Detection, ctDNA
MRD

May require more time and resources

Abbreviations: AS-PCR, allele-specific PCR; AMRS, Amplification Refractory Mutation System; dPCR, digital PCR; ddPCR, digital droplet PCR; BEAMing, beads, emulsion, amplification,
and magnetics; ctDNA, circulating tumor DNA; MRD, minimal residual disease; NGS, next-generation sequencing; TAm-Seq, Tagged-Amplicon sequencing; Safe-SeqS, Safe Sequencing
System; SCNAs, somatic copy-number alteration; CAPP-Seq, Cancer Personalized Profiling by Deep Sequencing; TEC-Seq, Targeted Error Correction Sequencing; GRP, Genome
Representation Profiling; WES, whole exome sequencing; WGS, Whole Genome Sequencing; cfMeDIP-seq, Cell-Free methylated DNA immunoprecipitation-sequencing; cfMBD-seq,
cell-free methyl-CpG binding proteins; DELFI, DNA evaluation for early interception; cfDNA, cell-free DNA. Adapted from [23] Thoracic Surgery Clinics, Pellini, B.; Szymanski, J.; Chin,
R.-I.; Jones, P.A.; Chaudhuri, A.A. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer. Thorac. Surg. Clin. 2020, 30, 165–177. Copyright 2020, with permission
from Elsevier, and adapted with permission from Springer Nature [55]: Springer Molecular Diagnostics & Therapy. Chin, R.-I.; Chen, K.; Usmani, A.; Chua, C.; Harris, P.K.; Binkley, M.S.;
Azad, T.D.; Dudley, J.C.; Chaudhuri, A.A. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). Mol. Diagn. Ther. 2019, 23, 311–331.
Copyright 2019.
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3. Molecular Profiling
Over the past two decades, pivotal discoveries in lung cancer biology and landmark
clinical trials with the introduction of targeted therapy and immunotherapy have led to
major transformations in the treatment paradigm for NSCLC [56,57]. Historically, patients
with NSCLC were treated with first-line histology-based cytotoxic doublet chemotherapies [58,59]. With the discovery of specific activating gene alterations (e.g., EGFR), preclinical development and the clinical validation of respective targetable therapeutics for
oncogene-driven NSCLC has led to the approval of new targeted therapies [56,60–65]. As
the focus of NSCLC therapy shifted to a more personalized approach, knowledge of molecular biomarker status has essentially become a prerequisite for providing comprehensive
care in thoracic oncology [66,67]. Traditionally, the detection of oncogenic driver alterations
has required available and adequate tumor tissue to perform immunohistochemistry (IHC)
or single-gene polymerase chain reaction (PCR) assays [32,56,66]. Single-gene quantitative PCR (qPCR)-based assays can be time-consuming and exhaustive to test on tissue
across the vast array of actionable mutations (Table 1). Moreover, tissue-based genotyping after disease progression while on therapy requires obtaining a tissue re-biopsy that
could be challenging for various reasons (e.g., technically difficult tumor locations) [23].
Furthermore, qPCR-based assays are inherently confirmatory for a genotype-informed
allele-specific alteration (e.g., EGFR L858R) but are not investigative for rare sequence
alterations [68].
A major advancement in the field of oncology was the development of minimally
invasive methods of tumor genotyping, including digital droplet PCR (ddPCR) and nextgeneration sequencing (NGS). ddPCR is a digital PCR technology that emulsifies plasma
DNA into thousands of droplets, which are then amplified using PCR methods, fluorescently labeled, and read with an automated droplet flow cytometer [34,69,70]. Oxnard et al.
demonstrated via proof-of-principle the utility of ddPCR to perform minimally invasive
genotyping of plasma ctDNA samples from patients with KRAS-mutant and EGFR-mutant
NSCLC, showcasing the high sensitivity and specificity of this technology [71]. In contrast
to ddPCR, targeted NGS utilizes a gene panel to query multiple plasma ctDNA mutations
in parallel [23,55]. While these assays generally have high sensitivity and specificity for
detecting single nucleotide variants (SNVs), initial NGS-based methods had insufficient
sensitivity for the detection of chromosomal copy-number alterations and rearrangements
(Table 1) [46,72]. To improve sensitivity and reduce error rates, massive parallel sequencing
techniques, such as the Safe-Sequencing System (Safe-SeqS) [38] and error-suppressed multiplexed deep sequencing [37,73], were developed (Table 1). In a study of 48 patients with
advanced NSCLC, bias-corrected targeted NGS interrogating 11 targetable oncogenic driver
genes in NSCLC was applied [74]. Mutations were identified to a depth of ≥0.4% of variant
allele frequency (VAF), with 100% sensitivity and specificity [74]. In addition, this NGS
approach identified a novel double-deletion in the EGFR exon 19 and MET amplification
that were previously missed by direct tissue sequencing despite four biopsies [74].
To overcome limitations in terms of cost, reduce the need for patient-specific optimization, and improve the sensitivity of detection (Table 1), Newman et al. developed
CAPP-Seq (Cancer Personalized Profiling by deep Sequencing), a hybrid capture-based
method of targeted NGS for ctDNA detection [40]. CAPP-Seq can detect all major classes
of genomic alterations, including SNVs, indels, copy-number variations (CNV), and rearrangements, with levels of detection for mutant allele fractions down to ~0.02% [40,41,68].
CAPP-Seq ctDNA profiling was employed to study resistance mechanisms in 43 patients
with advanced NSCLC who were treated with rociletinib, a third-generation EGFR TKI [75].
Using a biotinylated probe (selector) targeting 252 genes, the authors identified multiple
putative resistance mechanisms that emerged during rociletinib treatment in 46% of patients, including a novel EGFR L798I mutation [75]. These findings showcase the potential
of targeted NGS to detect mechanisms of resistance.
Historically, molecular rearrangements (i.e., fusions) are detected by utilizing either fluorescence in-situ hybridization (FISH) or IHC from tumor tissue specimens. However, due
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to operator dependency, the heterogeneity of breakpoints, small intrachromosomal deletion
events, and increasing numbers of novel fusion partner genes, clinical detection of molecular rearrangements by these methods carries high rates of false-positive and false-negative
results [76,77]. Anchored multiplex PCR (AMP), a NGS target enrichment method, was
developed by Zheng et al. for rapid and efficient gene arrangement detection [78]. This technique was applied to nucleic acids extracted from 319 formalin-fixed paraffin-embedded
(FFPE) samples from different solid tumors, including lung adenocarcinoma, and demonstrated 100% sensitivity and specificity to detect gene rearrangements when compared
with standard clinical FISH assays [78]. Moreover, the authors demonstrated its potential
for identifying new therapeutically important gene fusions in NSCLC [78]. In another
study, tumor-specific alterations in ROS1 were identified by proprietary Guardant360®
NGS technology, utilizing plasma from patients with ROS1-positive NSCLC [79]. The
assay demonstrated 100% concordance in the detection of ROS1 fusions between tissue
and plasma genotyping performed for seven patients [79]. CD74 predominated as the most
common fusion partner, among seven novel fusion partners that were identified [79].
To understand if targetable kinase fusions can be reliably identified in plasma with
comprehensive genomic profiling, the pan-tumor landscape of 16 targetable kinase fusions
was tested on and validated across 36,916 blood samples and 368,931 tumor tissue samples,
utilizing proprietary FoundationOne® NGS technology [45]. The investigators reported
that 88% of patients had detectable ctDNA in plasma, among whom 1.8% had detectable
kinase fusions [45]. A 92% concordance rate was noted in the 63 available paired tissue
and plasma samples, validating the utility of NGS technologies to detect ctDNA-derived
fusions [45]. In fact, among 32 patients with fusions detected in plasma but not in tissue,
66% had new fusions that represented mechanisms of acquired resistance to therapy [45].
Commercially available multigene panels have revolutionized patient care in the 21st
century, leading to the FDA approval of two liquid biopsy assays (Table 1): Guardant360®
CDx [25,43,44] and FoundationOne® Liquid CDx [26,80]. In 2020, both of these hybrid
capture-based, targeted NGS assays were approved for clinical application to identify
genomic alterations in patients with advanced-stage solid malignancies. To address the
suboptimal detection of ctDNA in patients with NSCLC who were afflicted with brain
metastases, a prospective study explored the utility of radiographic metrics and NGS testing
on CSF for ctDNA detection [81]. Further clinical development of predictive modeling
is needed to better understand the features of brain metastases, which may improve the
detection of CSF ctDNA [81].
4. Treatment Response Monitoring
The introduction of targeted therapy for patients with advanced NSCLC has prompted
an ongoing search to identify personalized biomarkers that predict which patients will
have durable clinical benefits with treatment [82,83]. Unfortunately, selective pressure
with targeted therapy drives molecular evolution, wherein the monitoring of response
and the detection of mechanisms of acquired resistance are necessary for the expedient
management of patients after disease progression while on therapy [84,85].
A study by Murtaza et al. enrolled six patients with advanced breast cancer, ovarian
cancer, and NSCLC who were serially followed over 1 to 2 years, using the exome-wide
analysis of plasma ctDNA to quantify mutation allele fractions [46]. Patient LUN-209, with
advanced NSCLC, progressed on treatment with gefitinib after 109 days, corresponding
with the emergence of a resistance-conferring EGFR T790M mutation detected by digital
PCR of plasma ctDNA. This result established proof-of-principle that plasma ctDNA can
be used to identify emergent mutations involved in the clonal evolution of acquired drug
resistance in NSCLC [46].
FASTACT-2 [86], a randomized study of intercalated erlotinib versus placebo use
among patients receiving 6 cycles of platinum-based therapy for advanced NSCLC, included serial plasma collection from 305 patients at baseline, after cycle 3, and at disease
progression to assess for EGFR mutations using the cobas® EGFR Mutation Test, a real-
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time PCR test [33,86,87]. Blood-based testing for EGFR ctDNA exhibited 75% sensitivity
and 96% specificity, as well as 88% concordance to matched tumor tissue [87]. A median
progression-free survival (PFS) benefit was observed in patients with detectable EGFR
mutations in ctDNA vs. EGFR wild-type ctDNA at baseline who had received erlotinib
(13.1 vs. 6.0 months; HR, 0.22; 95% CI: 0.14–0.33) [87]. Interestingly, patients with detectable
EGFR mutations in blood plasma at baseline and who did not clear the EGFR mutation
after 3 cycles had a shorter PFS (7.2 vs. 12.0 months; HR, 0.32; 95% CI: 0.21–0.48) and worse
overall survival (OS) (18.2 vs. 31.9 months; HR, 0.51; 95% CI: 0.31–0.84) [87].
A retrospective study performed by Phallen et al. assessed serial liquid biopsies from
28 patients with advanced NSCLC, who were undergoing treatment with targeted TKIs, to
measure the ctDNA dynamics and predict clinical outcomes [88]. Specifically, blood draws
performed at baseline and serial timepoints were analyzed with ultrasensitive targeted error
correction sequencing (TEC-Seq) and whole-genome sequencing to identify tumor-derived
alterations in ctDNA, such as somatic variants and chromosomal copy-number alterations
(Table 1) [88]. The results revealed a bimodal distribution of cell-free tumor load after the
initiation of TKI therapy (median time of 19 days), whereas ctDNA responders showed
the near-complete elimination of cell-free tumor load at early follow-up (cell-free tumor
load reduction > 98%) compared to ctDNA non-responders (cell-free tumor load reduction
≤ 98%). The ctDNA responders had a significantly prolonged PFS (median of 13.7 vs.
1.6 months; HR 66.6; 95% CI: 13.0–341.7 months) [88]. Tumor response, including ctDNA
non-responders, was detected on average 4 weeks earlier than radiographic assessment,
highlighting the potential role of comprehensive genome-wide ctDNA analysis for the
earlier evaluation of tumor burden in response to targeted therapies [42,88,89].
LungBEAM, a prospective study across 19 Spanish hospitals, collected serial blood
specimens at baseline from 110 treatment-naïve patients with advanced EGFR-mutant
NSCLC and monthly for EGFR T790M emergence while on first-line EGFR TKI therapy
until radiographic progression [90]. Progression was observed in 68 of the 110 patients
(61.8%) who completed the study. Twenty-six patients (23.6%) showed the presence of
an EGFR T790M mutation in plasma, with detection at a median of 76 days prior to
radiographic progression [90].
The ALEX study (NCT02075840) compared two ALK inhibitors, alectinib and crizotinib, in the first-line setting via a randomized trial for patients with advanced ALK-positive
NSCLC [91]. A retrospective analysis utilizing samples from the ALEX study found a positive correlation between cfDNA concentration and the number of lesions, organ lesion sites,
and tumor size. OS data remains immature [92]. Further prospective trials utilizing ctDNA
to predict treatment responses in NSCLC are underway (Table 2).
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Table 2. Ongoing clinical trials actively investigating the role of ctDNA in personalized treatment in patients with NSCLC.
Trial (NCT #)

Primary
Treatment

Stage

Estimated
Enrollment

Recruitment
Status

ctDNA Timepoint

ctDNA (+)
Intervention

ctDNA (−)
Intervention

Phase

Primary
Endpoint

Type of Assay

SCION
(NCT04944173)

SBRT+ 4 cycles
of durvalumab

T1-2
N0
M0

94

Not yet
recruiting

After SBRT + 4
cycles durvalumab

Additional 8 cycles of
durvalumab

No further treatment

II

ORR at
18 months

Avenio

SoC durvalumab
(10 mg/kg every
2 weeks, or
equivalent, for
1 year)

III

Change in
ctDNA level
following
chemo

Avenio

NCT04585490

CRT

III

48

Recruiting

After CRT

Four cycles of platinum
doublet
chemo + durvalumab
(1500 mg IV every
21 days, for 1 year)

NCT04585477

Surgery or
definitive SBRT

I–III

80

Recruiting

After surgery or
SBRT

Twelve cycles of
durvalumab

SoC and no
treatment

II

Decrease in
ctDNA level

Avenio

MERMAID-1
(NCT04385368)

Resection of
primary NSCLC

II–III

332

Active, not
recruiting

After surgery

Durvalumab + SoC
chemo
vs.
placebo + SoC chemo

N/A

III

DFS in MRD+
analysis set

ArcherDx

MERMAID-2
(NCT04642469)

Surgery +/−
neoadjuvant or
adjuvant Tx

284

Active, not
recruiting

After surgery

Durvalumab
vs.
placebo

III

DFS in the
PD-L1 TC ≥
1% analysis
set

ArcherDx

II–III

N/A

Abbreviations: chemo, chemotherapy; DFS, disease-free survival; MRD, minimal residual disease; NSCLC, non-small cell lung cancer; ORR, overall response rate; SBRT, stereotactic body
therapy; Tx, treatment.
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The search for the perfect biomarker to predict disease response to immune checkpoint
inhibition (ICI) and demonstrate improvements in OS remains elusive [93–95]. Several
novel candidate biomarkers have been investigated, including tumor PD-L1 [93,96], tumor
mutational burden (TMB) [97,98], mismatch repair deficiency [99], mutations in FAT1 [100],
and lymphocyte infiltration in the tumor microenvironment [94,101], with mixed evidence to accurately predict the response to ICI [95]. A proof-of-concept prospective study
(NCT02866149) in patients with advanced NSCLC, uveal melanoma, or microsatelliteunstable colorectal cancer (CRC), who were treated with standard-of-care anti-PD-1 therapy (pembrolizumab or nivolumab) compared ctDNA monitoring at baseline and week
8 of treatment, with tumor response established by radiological evaluation [102]. The
ctDNA levels were detected via bidirectional pyrophosphorolysis-activated polymerization (bi-PAP) assay, ddPCR, or targeted-NGS with a focused panel of 39 cancer-related
genes. At baseline, ctDNA was detected in 10 of 15 patients [102]. ctDNA detection at
week 8 of treatment was a significant prognostic factor for shorter PFS (HR, 10.2; 95% CI:
2.5–41) and OS (HR, 15; 95% CI: 2.5–94.9). This landmark study demonstrated the role of
ctDNA monitoring as a tool for treatment monitoring with anti-PD-1 immune checkpoint
inhibitors [102].
One challenge that exists in the field of immuno-oncology is the interpretation of
early radiographic response and misinterpretation of imaging, given potential pseudoprogression or delayed tumor shrinkage with initial cycles of treatment [103,104]. To offer
earlier indications of efficacy with ICI, a single institution study investigated serial ctDNA
levels by high-throughput DNA sequencing in 28 patients diagnosed with metastatic
NSCLC, who were actively receiving immunotherapy (anti-PD-1 or anti-PD-L1 alone, or
with other immunotherapy agents) [105]. CT scans were obtained within 30 days before
the first treatment and serially at 6- to 12-week intervals, or when clinically indicated.
Blood samples were collected on day 1 (prior to treatment) and with routine blood draws,
typically at intervals of 2 or more weeks [105]. Concordance between ctDNA response
and radiographic response was observed (Cohen’s kappa, 0.753) [105]. ctDNA response
(>50% reduction in level from baseline) was observed earlier than the radiographic response per RECIST version 1.1 (median of 24.5 vs. 72.5 days), where the time undergoing
treatment was significantly prolonged in ctDNA responders versus non-responders (median of 205.5 vs. 69 days, p < 0.001) [105]. While on ICI, ctDNA response was associated
with improved PFS (HR, 0.29; 95% CI: 0.09–0.89) and superior OS (HR, 0.17; 95% CI:
0.05–0.62) [105].
In 2018, Raja et al. demonstrated that changes in the VAFs of somatic mutations in
ctDNA were strongly correlated to the outcomes of patients treated with durvalumab [106].
Samples from 28 patients were utilized from Study 1108 (NCT01693562), which investigated the role of durvalumab in patients with advanced NSCLC who had progressed,
been ineligible for, or refused any number of prior therapies [106]. Independent validation was performed in 72 patients with advanced EGFR wild-type NSCLC from cohort
2 of the ATLANTIC study (NCT02087423), which assessed the effect of durvalumab for
the treatment of patients with Stage IIIB/IV NSCLC, who progressed following two or
more systemic treatments [107]. One or more somatic variants, including SNV, indels,
fusions, and silent mutations, were detected in the ctDNA of 27 of 28 patients (96%) at
pre-treatment baseline [106]. Patients with a decrease in mean VAF had a median treatment
duration of 22 months compared to 6.5 months for patients with an increase in mean VAF
(p < 0.001) [106].
Among three phase-I/II studies (Study 1108, ATLANTIC, and Study 10) with durvalumab alone or in combination with tremelimumab, conducted across 16 advanced-stage
tumor types, Zhang et al. demonstrated similar findings where pre-treatment and ontreatment ctDNA dynamics serve as prognostic and predictive biomarkers for long-term
survival on ICI, respectively, coining the concept of a “molecular response metric”, using
ctDNA as a valuable tool to complement radiographic changes in trial endpoints [108].
Similarly, Anagnostou et al. demonstrated that among 24 patients with metastatic NSCLC

Int. J. Mol. Sci. 2022, 23, 9006

10 of 24

treated with ICI, ctDNA non-responders had shorter PFS (median of 5.2 vs. 14.5 months;
HR, 5.36; 95% CI: 1.57–18.35) and OS (median of 8.4 vs.18.7 months; HR, 6.91; 95% CI:
1.37–34.97) compared to ctDNA responders [109]. Moreover, ctDNA response detected
disease progression on average 8.7 weeks earlier than CT imaging [109].
In another study by Ricciuti et al., where 62 patients with advanced NSCLC were
treated with first-line pembrolizumab, plus or minus platinum-based chemotherapy, significant correlations between rapid decreases in ctDNA with higher response rates (60.7%
vs. 5.8%, p = 0.0003), improvements in median PFS (8.3 vs. 3.4 months, HR, 0.29; 95%
CI: 0.14–0.60, p = 0.0007), and median OS (26.2 vs. 13.2 months, HR, 0.34; 95% CI: 0.15–
0.75, p = 0.008) were noted [98]. Comparable results were reported in a single-center,
prospective study at the University of Pennsylvania investigating the role of serial ctDNA
levels as a predictive biomarker for therapeutic response to pembrolizumab-based therapy
(i.e., monotherapy or in combination with chemotherapy) [110]. Specifically, 67 patients
had plasma samples collected at baseline (prior to treatment initiation) and at 9 weeks of
treatment. The samples were analyzed via 74-gene panel NGS assays (Guardant360® and
GuardantOMNI™) [110]. Patients who achieved a molecular response, defined by >50%
decrease in mean VAF, showed meaningful durable clinical benefit (DCB) with significantly
longer PFS (HR, 0.25; 95% CI: 0.13–0.50) and OS (HR, 0.27; 95% CI: 0.12–0.64), compared to
molecular non-responders [110].
In an effort to refine ctDNA prediction modeling with a novel multiparameter biomarker
for long-lasting immunotherapy response, Nabet et al. developed and validated a robust
minimally invasive multiparameter assay to reflect the immune milieu, termed DIREctOn (durable immunotherapy response estimation by immune profiling and ctDNA-On
treatment) [111]. Pre-treatment specimens were collected from 99 patients with advanced
NSCLC, who were treated with anti-PD-L1, including tumor biopsies for PD-L1 expression, plasma ctDNA for analysis using CAPP-Seq, and leukocyte profiling by CIBERSORT
and/or flow cytometry [111]. Patients were split into 3 cohorts for early on-treatment
downstream analysis (within 4 weeks from start, median 2.4 weeks), including (1) feature discovery analysis (n = 22), (2) training set for DIREct Discovery Cohort (n = 34), or
(3) testing set for DIREct Validation Cohort (n = 38) [111]. Of 99 patients, 94 had detectable
pre-treatment ctDNA with CAPP-Seq [111]. Investigators demonstrated that lower pretreatment ctDNA levels and lower baseline circulating CD8 T cell levels (accuracy = 70%)
are independent variables associated with DCB [111]. Early on-treatment ctDNA levels decreased > 50% from baseline in 59% of patients, and this metric outperformed all individual
pre-treatment factors to predict DCB (p < 0.05, accuracy = 73%). The ctDNA dynamics were
also significantly associated with improved PFS (p = 0.013, HR = 2.28) [111]. Utilizing a
Bayesian approach incorporating tumor-cell intrinsic and extrinsic determinants for ICI benefits, including PD-L1 expression, normalized bTMB, circulating CD8 T cells for DIREct-Pre,
plus ctDNA dynamics for DIREct-On were trained, tested, and validated [111]. Investigators reported that patients with higher DIREct-On scores had significantly longer PFS
than those with low DIREct-On scores (mPFS 8.1 vs. 2.1 months, respectively, p < 0.0001,
HR = 7.11) [111]. DIREct-On demonstrated superiority in the prediction of PFS, compared
to ctDNA dynamics (p < 0.01), CD8 T cell fraction (p < 0.01), and bTMB (p < 0.05) alone.
Prospective trials utilizing DIREct-On to validate clinical utility are anticipated [111].
5. Minimal Residual Disease (MRD) Detection
MRD is defined as a microscopic volume of tumor cells that remain after curativeintent treatment, yielding significantly lower levels of ctDNA in plasma (often below
0.1% of total cfDNA) relative to advanced-stage disease [55]. In the MRD setting, either
tumor-informed or tumor-naïve assays can be used to detect ctDNA [112,113]. Tumorinformed assays utilize prior mutational knowledge via the sequencing of tumor tissue to
interrogate plasma samples for patient-specific mutations [39,114,115]. Tumor-naïve assays
perform de novo variant-calling using a preselected panel of hotspot mutations to query
multiple loci simultaneously across a genomic scale [116,117]. A tumor-informed approach
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is associated with certain advantages (e.g., customization to an individual patient and
ability to track multiple simultaneous tumor-specific mutations) and disadvantages (e.g.,
limited clonal variant detection and increased turnaround time) compared to tumor-naïve
assays. Nonetheless, both approaches, in conjunction with target enrichment (e.g., PCR or
hybrid-capture) and false-positive error suppression (e.g., sequencing of PBMCs to filter CH,
molecular barcoding, and in silico elimination of stereotypical artifacts), seek to minimize
background noise and enable greater sequencing depths of tumor-derived mutations for
highly sensitive MRD detection (Table 1) [112,113]. Although commercially available assays
for MRD detection have not yet been approved by the FDA to be used in clinical practice in
patients with NSCLC, several groups have sought to demonstrate ctDNA MRD as a viable
biomarker for predicting disease relapse and treatment response, particularly for patients
with NSCLC after curative-intent treatment (Figure 2) [39,112,116,117].

Figure 2. Timeline of ctDNA MRD studies in patients with NSCLC. A timeline of studies that have
advanced our understanding of ctDNA MRD as a prognostic and potentially predictive biomarker in
patients with NSCLC, who were treated with a curative-intent [39,115–122].

In 2017, Abbosh et al. demonstrated that ctDNA MRD detection after surgical resection
in patients with stages I-III NSCLC was associated with disease relapse. The twenty-four
patients included in this analysis were enrolled onto the TRACERx study (NCT01888601),
a multicenter prospective trial designed to study the evolutionary dynamics of NSCLC in
over 800 patients [39]. The authors applied Signatera™ (Natera, San Carlos, CA, USA), a
tumor-informed assay that utilizes a patient-specific multiplex PCR to sequence cfDNA,
to the plasma of 24 patients with stage IA-IIIB NSCLC, following surgical resection plus
or minus adjuvant therapy and post-operative radiation [39]. Among 14 patients with
disease relapse, five patients (36%) had detectable ctDNA at the first timepoint after
surgery (i.e., within 30 days) [39]. Upon longitudinal plasma sampling from these patients
(i.e., surveillance), 93% of the patients who eventually developed disease recurrence had
detectable ctDNA MRD before or at the time of clinical relapse [39]. For the 10 patients who
remained relapse-free, ctDNA MRD was not detected in 90% and 70% of patients at the
first timepoint of collection and in the surveillance setting, respectively [39]. Of note, the
single patient with a false-positive detection of ctDNA at the first timepoint after surgery
then received both adjuvant chemotherapy and radiation therapy, which likely ablated
MRD since ctDNA became undetectable at three serial timepoints following the completion
of adjuvant therapy [39]. Conversely, three patients with detectable ctDNA at the first
timepoint after surgery had rising ctDNA levels following adjuvant chemotherapy, and all
three patients relapsed within one year [39]. Altogether, these findings show that ctDNA
MRD, as well as ctDNA dynamics, may inform clinicians regarding the risk of disease
relapse following the curative-intent treatment of resectable NSCLC.
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Chaudhuri et al. published the first study demonstrating the promise of ctDNA MRD
as a prognostic biomarker for patients with unresectable NSCLC who underwent curativeintent treatment [116]. The authors applied CAPP-Seq, which utilizes hybrid capture-based
NGS with a panel of 128 genes that are recurrently mutated in lung cancer, to sequence
cfDNA from the plasma of 37 patients with stage IB-IIIB NSCLC, most of whom underwent
concurrent chemoradiation (CRT), alongside three patients with limited-stage small cell
lung cancer [116]. Among 32 patients with evaluable samples, 17 patients had detectable
ctDNA at the first timepoint within four months of treatment completion [116]. These
patients had a significantly shorter freedom from progression (FFP) and disease-specific
survival (DSS) rate relative to those with undetectable ctDNA at the same timepoint [116].
Moreover, all 14 patients who remained relapse-free had undetectable ctDNA, showcasing
the high specificity of CAPP-Seq for MRD detection [116]. When monitoring post-treatment
ctDNA in the surveillance setting at multiple timepoints, both the sensitivity and specificity
of CAPP-Seq for predicting relapse were 100% [116]. Of note, the detection of ctDNA MRD
preceded radiographic relapse via routine CT imaging in 72% of patients by a median
of 5.2 months [116]. These findings provide strong evidence for the potential of ctDNA
MRD as a prognostic biomarker in patients with unresectable NSCLC after curative-intent
treatment; moreover, they encourage future prospective studies to assess the clinical utility
of ctDNA MRD in improving the selection of patients for consolidation therapy and possible
treatment de-escalation.
In 2019, Chen et al. published findings from the DYNAMIC study (NCT02965391) [118].
This trial aimed to investigate perioperative ctDNA dynamic changes in patients with
NSCLC after an R0 resection (i.e., microscopically margin-negative) [118]. The authors
applied cSMART, which utilizes multiplex PCR using a panel of eight commonly mutated genes in NSCLC, to amplify plasma ctDNA from 205 study participants, of whom
36 had detectable ctDNA in their preoperative samples [118]. As expected, both plasma
ctDNA concentrations and mutant allele fractions rapidly decreased after surgical resection,
suggesting that post-operative ctDNA reflects real-time tumor burden [118]. Next, the authors sought to determine the timepoint at which detectable ctDNA after R0 resection had
prognostic value [118]. Based on the prospective follow-up of 25 evaluable patients with
multiple plasma samples collected after surgery (e.g., 1, 3, and 30 days post-operatively),
the detection of ctDNA MRD three days after surgery was significantly associated with
worse recurrence-free survival (RFS) and OS, relative to undetectable ctDNA MRD at
this timepoint (median RFS of 278 vs. 637 days, and median OS of 434 vs. 720 days,
respectively) [118]. Of note, the authors did not find an association between ctDNA MRD
detection at one day after surgery and outcomes, suggesting that this timepoint is likely too
early to detect microscopic residual disease due to a high rate of false-positives [118]. These
combined findings suggest that detectable ctDNA MRD as early as three days after surgery
is prognostic for disease relapse. This timepoint may be used for ctDNA MRD analysis in
future clinical trials assessing adjuvant treatment escalation and possible de-escalation for
such patients.
In 2020, Moding et al. sought to assess the potential of ctDNA MRD as a biomarker to
stratify which patients would receive the most benefit from consolidation immunotherapy
after CRT completion [117]. Using CAPP-Seq [40], the authors sequenced plasma cfDNA
from 65 patients with unresectable stage IIB-IIIB NSCLC who were treated with CRT, of
whom 28 also received consolidation ICI [117]. Pre-treatment ctDNA was detected in 78%
of patients who did not receive consolidation ICI and in 75% of patients who received consolidation ICI [117]. Among 22 patients with serial ctDNA samples collected after starting
consolidation ICI, 6 out of 7 patients (86%) with detectable ctDNA early on-consolidation
ICI (i.e., median of 11 weeks into consolidation ICI) developed progressive disease, compared to only 2 out of 15 patients (13%) with undetectable ctDNA at this timepoint [117].
Furthermore, detectable ctDNA during early on-consolidation ICI conferred a significantly
higher risk of disease progression than undetectable ctDNA (FFP of 0% vs. 87.5%, respectively, at 12 months after starting CRT) [117]. These findings suggest that ctDNA analysis
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after starting ICI can detect residual disease and is prognostic of disease recurrence. Among
patients with undetectable ctDNA after CRT, the authors did not observe a statistically
significant difference in FFP, regardless of whether consolidation ICI was received or not
(p = 0.23) [117]. In contrast, patients with detectable ctDNA after CRT showed significantly
better FFP when consolidation ICI was received (p = 0.04) [117]. These findings suggest
that ctDNA MRD may help select those patients who are most likely to benefit from consolidation ICI and enable those without residual disease to avoid the potential toxicity of ICI
therapy. Of note, the study was not powered to detect a small benefit from consolidation
ICI among patients with undetectable ctDNA. Future prospective studies with large sample
sizes are required to demonstrate the non-inferiority of withholding consolidation ICI from
these patients. Lastly, the authors found that changes in ctDNA concentrations (i.e., ctDNA
dynamics) further clarified which patients among those with detectable ctDNA after CRT
responded to consolidation ICI. Patients with decreasing ctDNA levels after starting consolidation ICI achieved a longer FFP, compared to those with increasing ctDNA levels
(median of 22 vs. 5 months, respectively) [117]. Indeed, patients with increasing ctDNA
levels, despite starting consolidation ICI, did not have a significantly better FFP (p = 0.47)
than patients with detectable ctDNA who did not receive consolidation ICI [117]. Thus,
ctDNA monitoring during consolidation ICI may help to identify the subset of patients
whose tumors will fail to respond to immunotherapy and who might benefit from either
treatment escalation or a change in systemic therapy. However, the authors only performed
an analysis of plasma ctDNA at a single early on-consolidation timepoint, which is clinically
important to facilitate earlier intervention in the setting of treatment resistance but may
precede the timepoint when some patients respond to immunotherapy. Future studies
should investigate multiple timepoints during consolidation ICI to confirm these findings.
Updated findings from the TRACERx study were presented at the American Association for Cancer Research Annual Meeting in 2020 [115]. In their follow-up analysis, the
authors applied PCM™ (ArcherDx, Inc., Boulder, CO, USA), a tumor-informed ctDNA
assay targeting 196 patient-specific tumoral variants using a personalized multiplex PCR
to sequence plasma ctDNA [115]. Study investigators analyzed samples from 78 patients
with resectable stage I–III NSCLC [115]. Among the 45 patients that developed disease
relapse during follow-up, 82% had a positive ctDNA MRD assay before or at the time of
disease recurrence, showcasing this assay’s high sensitivity for detecting disease relapse.
Furthermore, only one of the 23 patients without disease recurrence had a positive ctDNA
MRD during follow-up, demonstrating the high specificity of PCM™ to detect MRD [115].
In 2020, Zviran et al. developed MRDetect (C2i Genomics, New York, NY, USA),
which overcomes the constraint on sensitivity imposed by a low disease burden after
surgery [119]. The authors showed that a tumor-informed analysis, combining thousands
of SNVs and CNAs detected by whole-genome sequencing (WGS) of tumor tissue [47,48],
can achieve highly sensitive ctDNA detection in the case of tumor fractions as low as 10−5 ,
despite a low depth of coverage [119]. They applied MRDetect to plasma samples collected
from 22 patients with stage I–III NSCLC after surgical resection [119]. Among 5 patients
who relapsed, all had detectable ctDNA, while 12 of the 17 remaining patients who were
relapse-free did not have detectable ctDNA, showcasing this assay’s high sensitivity and
reasonable specificity to predict disease relapse [119]. Future studies with larger patient
cohorts will be important to validate the promising sensitivity of this WGS-based assay for
patients with NSCLC after surgical resection.
In 2021, Kurtz et al. developed a new technology, termed Phased Variant Enrichment
and Detection Sequencing (PhasED-Seq) (Foresight Diagnostics Inc., Aurora, CO, USA), to
improve the sensitivity of ctDNA MRD detection [120,123]. Assays that utilize molecular
barcoding, such as CAPP-Seq, rely on duplex sequencing to improve the limit of detection,
but duplex strand recovery is often suboptimal in the MRD setting [41,124]. PhasED-Seq
instead focuses on the detection of multiple mutations within the same strand of DNA
(i.e., phased variants), foregoing the need to recover duplex strands to increase the efficiency
of genome recovery [123]. Using this novel strategy, the authors showed that PhasED-Seq
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outperforms duplex sequencing with CAPP-Seq, yielding a limit of detection below one
part per million [123]. PhasED-Seq was then applied to 14 plasma samples, collected from
five patients with localized NSCLC, for MRD detection [120]. PhasED-Seq detected ctDNA
MRD in 10 of the 14 samples, while a SNV-based ctDNA method only detected MRD in 5 of
the 14 samples. Furthermore, the authors compared both methods to detect MRD in three
longitudinal samples from a patient with unresectable stage III NSCLC who underwent
curative-intent treatment with CRT and consolidation ICI [120]. While the SNV-based
method failed to detect ctDNA MRD in all of the samples, PhasED-Seq detected ctDNA
MRD at each of these timepoints [120]. These findings suggest the potential of PhasED-Seq
as an ultrasensitive method for ctDNA MRD detection in patients with NSCLC. Future
studies are warranted to validate its sensitivity in larger patient cohorts.
Xia et al. conducted a large prospective cohort study, aiming to validate previous
findings that perioperative ctDNA MRD detection is prognostic for disease relapse after
surgical resection in patients with stages I-III NSCLC [121]. Nine hundred and fifty plasma
samples from 330 evaluable patients enrolled on the LUNGCA-1 study (NCT03317080) were
collected and analyzed using a tumor-informed assay. The majority of patients had a diagnosis of stage I NSCLC; the most common histological subtype was lung adenocarcinoma
(LUAD) [121]. Plasma samples were collected before surgery, 3 days after surgery, and
1 month after surgery. Only 20.9% of patients had detectable ctDNA before surgery. Among
those, ctDNA MRD detection at either 3 days or 1 month after surgery was associated with
a higher rate of disease relapse (HR = 11.1, p < 0.001) [121]. Xia et al. further demonstrated
that pre-operative ctDNA positivity was also associated with lower RFS (HR, 4.2; p < 0.001),
although, interestingly, it was only prognostic among patients with LUAD and not lung
squamous cell carcinoma (LUSC) [121]. Of note, ctDNA MRD detection outperformed
all other clinicopathologic variables studied, including TNM stage, for predicting disease
relapse. Adjusting for these other variables, adjuvant therapy improved RFS for patients
with positive ctDNA MRD detection [121]. Interestingly, patients with negative ctDNA
MRD showed worse RFS when receiving adjuvant chemotherapy compared to the ones
who did not receive it (HR, 3.1; p < 0.001) [121]. These results reinforce the prognostic value
of ctDNA detection after surgery for patients with early-stage NSCLC and showcase its
potential to inform adjuvant therapy selection and possible treatment de-escalation.
Waldeck et al. aimed to assess the optimal timepoint of blood collection for ctDNA
analysis among patients with stages IA-IIIB NSCLC who were undergoing surgical resection [122]. The authors prospectively enrolled 33 patients with resectable NSCLC in
their study. Twenty-one patients were evaluable for longitudinal ctDNA analysis before
surgery, during surgery, 1–2 weeks after surgery, and during clinical follow-up [122]. The
authors showed that samples collected during surgery, taken immediately before tumor
resection, had higher ctDNA levels compared to samples collected before surgery [122].
They hypothesized that physical manipulation of the tumor during surgery contributes to
ctDNA shedding. They also demonstrated that ctDNA MRD detection at 1–2 weeks after
surgery is prognostic of disease relapse after curative-intent resection [122]. While other
studies have supported the prognostic value of ctDNA MRD detection as early as 3 days
after surgery, due to the rapid clearance of ctDNA after tumor resection [118], the authors
of this study suggest that a later timepoint for collection at the time of hospital discharge or
at the first post-operative follow-up may be more practical and may have a lower risk of
false-positives.
Plasma genotyping techniques have significantly evolved over the past few decades.
However, despite the improvement in genomic coverage offered by newer technologies, all
detection methods face similar technical and biological challenges, including low amounts
of ctDNA in plasma, high levels of non-tumoral cfDNA arising from endothelial cells and
PBMCs, CH, passenger mutations, and background noise (e.g., DNA oxidative damage,
PCR errors, and sequencing artifacts) [23,55]. While bioinformatics pipeline refinement
has overcome certain technical challenges, such as background noise [41], CH represents
a major challenge when trying to implement ctDNA assays for MRD detection. One way
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to distinguish CH from tumoral variants is to perform parallel sequencing of PBMCs and
plasma and exclude those variants present in PBMCs from the list of variants detected
in plasma, as previously described [116,125]. While passenger mutations may not be
therapeutically relevant, their detection has been reported to be important for ctDNA
MRD detection [116,125]. In the context of treatment monitoring, these mutations also play
an important role as they may signal the emergence of treatment resistance. Given the
technical and biological limitations of ctDNA testing (Table 1), we recommend carefully
interpreting and applying results outside of a research context. Further studies with larger
patient populations are warranted to establish the clinical utility of ctDNA as a biomarker
to guide clinical decisions for patients with NSCLC who are treated with curative-intent,
along with its role in early cancer detection.
In summary, ctDNA MRD detection has been shown by multiple groups to be a prognostic biomarker in patients with stages I-III NSCLC, and it remains to be seen whether
ctDNA MRD detection can be used to predict treatment response and personalize treatment based on significant differences in survival outcomes. Multiple ongoing studies
are prospectively assessing treatment personalization based on ctDNA MRD detection
and will assess the clinical utility of ctDNA MRD as a biomarker for directing the clinical
management of patients with NSCLC (Table 2) [126–129].
6. ctDNA for Early Cancer Detection
A low-dose CT scan of the chest (LDCT chest) has been the current standard for lung
cancer screening in the US since the National Lung Screening Trial (NSLT) [130]. Within
this randomized trial, which compared annual LDCT chest for 3 years versus a single chest
radiography among asymptomatic participants at high-risk for lung cancer, the LDCT
chest was associated with a 20% relative reduction in mortality from lung cancer [130].
However, not all patients will benefit from an LDCT chest as current guidelines do not
recommend this screening test for patients without a smoking history or those who have
not smoked for many years [130]. Furthermore, LDCT chest has a 96% false-positive rate,
thus leading to an excessive use of diagnostic testing for asymptomatic individuals [130].
Incorporating ctDNA analysis into screening may help to address these issues by improving
the detection of lung cancer in a broader patient demographic and reducing the number of
diagnostic procedures.
The majority of LDCT chest findings are small pulmonary nodules and ground-glass
opacities, which may not be malignant or may shed very low concentrations of ctDNA [131].
Akin to the challenges of ctDNA detection in the MRD setting, two major challenges for
ctDNA detection during screening are a low VAFs, due to a small tumor volume, and
distinguishing tumor-derived mutations from CH [131]. However, as opposed to MRD
detection, screening does not provide the option of tumor-informed variant calling, thus
making it difficult to detect true biological mutations with a low VAF [131]. As shown
by data from the TRACERx study [39], ctDNA for a stage T1b NSCLC tumor of 1 cm is
present at an estimated VAF of 0.008% (95% CI: 0.002–0.03%), which is just beyond the
detection limit of most liquid biopsy technologies. Therefore, the early detection of stage
≤ T1b tumors via a tumor-naïve approach presents a significant challenge regarding the
effective implementation of ctDNA assays in lung cancer screening protocols [132].
Based on ctDNA detection via CAPP-Seq, Chabon et al. developed a machine-learning
method, termed “Lung Cancer Likelihood in Plasma” (Lung-CLiP), to estimate the likelihood that a given blood sample contains cfDNA derived from lung cancer, discriminated
from risk-matched controls [131]. In addition to tumor-naïve sequencing with a panel of
255 genes that are recurrently mutated in lung cancer, the authors leveraged the unique
properties of NSCLC-derived mutations relative to CH mutations (e.g., shorter cfDNA
fragment size and tobacco-smoking-associated mutational signatures) to reduce the rate
of false-positive variant calling [131]. Lung-CLiP was trained on a discovery cohort of
104 patients with early-stage NSCLC and 56 risk-matched controls who underwent annual
LDCT chest screening [131]. At a specificity of 98%, the algorithm yielded a sensitivity
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of 41% in patients with stage I disease, 54% in patients with stage II disease, and 67%
in patients with stage III disease [131]. Compared to tumor-informed ctDNA analysis,
Lung-CLiP achieves a similar level of performance without requiring tumor tissue genotyping [131]. Next, the authors prospectively validated Lung-CLiP in a cohort of 46 patients
with early-stage NSCLC and 48 risk-matched controls, all of whom were enrolled at a
different institution [131]. This independent validation demonstrated a statistically similar
level of performance within each stage of disease, thus supporting the external validity of
Lung-CLiP to predict the likelihood of lung cancer among similar types of patients [131].
Since most of the patients enrolled in this study were smokers and displayed incidentally diagnosed lung cancer, further work will be important to study the applicability of
Lung-CLiP to never-smokers and patients who otherwise undergo LDCT chest screening.
Methylation-based ctDNA analysis presents an alternative strategy for lung cancer
screening that largely avoids the issue of false-positives from CH mutations [49,50,133,134].
As part of the Circulating Cell-free Genome Atlas (CCGA) study, Liu et al. demonstrated a
method of targeted cfDNA methylation analysis for multi-cancer early detection [135]. The
authors applied bisulfite sequencing targeting a panel of >100,000 informative methylation
regions, identified from the first sub-study of CCGA, to plasma cfDNA samples from
6689 participants (2482 with cancer across > 50 different cancer types and 4207 without
cancer) [135]. Using a methylation-based classifier developed from a training set of the
cohort, independent validation yielded a specificity of 99.3%, with a <1% rate of falsepositives across all cancer types [135]. Sensitivity of stage I-III disease detection was 43.9%
in all cancer types and increased to 67.3% in a pre-specified set of 12 high-signal cancer
types, including lung cancer [135]. As expected, the sensitivity of detection improved with
increasing disease stage [135]. For lung cancer, sensitivity ranged from ~25% for stage I
disease to ~90% for stage IV disease [135]. Of note, localizing the tissue of origin (TOO)
was predicted with 93% accuracy [135].
Recently, Klein et al. published their findings from the third and final sub-study of
CCGA, a large clinical validation of the methylation-based classifier among 4077 independently enrolled participants (2823 with cancer and 1254 without cancer) [51]. Similar to
results reported from the second sub-study by Liu et al., the specificity for detecting cancer
was 99.5% [51]. For lung cancer, the sensitivity of detection across all stages was 74.8%,
ranging from 21.9% for stage I disease to 95.2% for stage IV disease. [51]. TOO was predicted with 88.7% accuracy [51]. Altogether, these results suggest that methylation-based
analysis of ctDNA for multi-cancer early detection may complement existing screening
tests for individual cancers. However, given that CCGA is a case-control study, further
work will be important for studying the utility of this methylation-based test for screening
populations. The ongoing SUMMIT study (NCT03934866) is specifically for UK NHS
patients who are at high risk of lung cancer, all of whom will have ctDNA analysis and
screening LDCT, with follow-up over several years [136].
In an effort to increase the sensitivity of early lung cancer detection, compared to
targeted sequencing of either mutations or methylation in ctDNA, Mathios et al. performed
a genome-wide analysis of cfDNA fragmentation profiles [52]. Their method, termed the
DNA evaluation of fragments for early interception (DELFI) [137], combines an analysis of
genome-wide cfDNA fragmentomes (i.e., evaluating the size distribution and frequency of
millions of cfDNA fragments) with clinical risk factors and CEA levels within a machine
learning model to detect lung cancer (Table 1) [52]. The authors assessed blood samples
from 365 participants who were enrolled in a prospective observational trial (LUCAS
cohort), most of whom were symptomatic individuals at high risk of lung cancer [52].
Among these individuals, 129 had lung cancer diagnosed by tissue biopsy after blood
collection, 87 had benign nodules, and 149 were not biopsied due to the low clinical and
radiographic suspicion of cancer [52].
Median DELFI scores were similar among individuals with benign lesions (0.21) versus those without a biopsy (0.16) and were significantly higher among patients with lung
cancer (ranging from 0.35 to 0.99 for stage I to stage IV, respectively) [52]. Among all
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patients in the LUCAS cohort, the DELFI approach detected lung cancer with an area
under the curve (AUC) of 0.90 [52]. The AUC increased to 94% when considering only
the majority of patients at higher risk for lung cancer (i.e., age 50–80 with a >20 pack per
year smoking history) [52]. The predictive performance of DELFI was externally validated
in an independent cohort of 385 participants without cancer and 46 participants with
predominantly early-stage cancer, and yielded similar levels of sensitivity and specificity
as in those observed by the model applied to the LUCAS cohort [52]. Furthermore, the incorporation of genome-wide cfDNA fragmentation data from the binding sites of ASCL1, a
transcription factor differentially overexpressed in small cell lung cancer (SCLC), may even
enable SCLC patients to be distinguished from NSCLC patients with an AUC of 0.98 [52].
Altogether, these findings suggest that ctDNA analysis via DELFI could potentially enhance lung cancer screening [52]. The authors propose a schema in which patients with
positive DELFI pre-screening may proceed to LDCT chest analysis for further diagnostic
workup [52]. DELFI-L101 (NCT04825834) is an ongoing prospective trial aiming to evaluate
a DELFI-based assay among individuals eligible for lung cancer screening [138]. Further
work will be important for assessing the utility of DELFI in combination with LDCT chest
and other markers of early lung cancer detection.
In conclusion, ctDNA analysis via mutational, methylation, and/or fragmentation
profiles offers promising potential for improving early lung cancer detection [53,54]. While
positive ctDNA screening alone may not be adequate, its minimally invasive nature can
provide a valuable pre-screening tool for a broader patient demographic and increase the
uptake and adherence of screening with LDCT chest. Perhaps, future studies for cancer
interception may utilize ctDNA technologies, such as DELFI and Grail Galleri™, for the
emergence of pre-cancerous lesions to lessen cancer burdens in high-risk patients with a
smoking history [51,52]. Therefore, future clinical studies centered on validating multi-omic
prediction models that integrate liquid biopsy markers and LDCT will be important for
optimizing lung cancer screening moving forward.
7. Conclusions
Liquid biopsies using ctDNA have the potential to enable the delivery of highly personalized treatment for patients with NSCLC. As an alternative to tumor tissue genotyping,
ctDNA may be used as a minimally invasive method for tumor molecular profiling to
identify actionable driver mutations that can guide treatment decision-making. In addition,
ctDNA can be used to identify patients who are responding to therapy or, conversely,
developing disease progression due to new genomic alterations. For patients who undergo
curative-intent therapy, ctDNA can detect MRD and is a strong prognostic biomarker for
disease relapse, but its clinical utility remains to be proven. Lastly, the multi-omic profiling
of ctDNA shows promising evidence for early cancer detection and may be an important
screening tool in addition to LDCT chest imaging. A major issue in the field is the lack
of technological standardization across different ctDNA assays. The technologies applied
for ctDNA analysis can impact assay performance since the sensitivity and specificity
of an assay vary substantially, depending on the limit of detection and bioinformatics
pipeline. Before selecting an assay, clinicians and researchers need to be familiar with the
technological limitations of the selected product and when to use such tests. While ctDNA
analysis is widely used in clinical practice for molecular profiling, the clinical utility of
these assays for treatment monitoring, MRD detection, and early cancer detection remains
to be proven. Therefore, ctDNA assays should not be used outside a research context
for these applications in patients with NSCLC. We anticipate that liquid biopsies will be
incorporated into the “TNM” staging system for lung cancer as an emerging metric for
more precise clinical staging, evaluation of treatment response, and MRD detection in the
future. Further studies with larger patient populations are warranted to establish the role
of ctDNA as a biomarker that can guide clinical decisions for patients with NSCLC who
are treated with curative-intent, as well as its role in early cancer detection.

Int. J. Mol. Sci. 2022, 23, 9006

18 of 24

Author Contributions: Conception and design: B.P., M.D.S. and K.C.; financial support: B.P.; administrative support: B.P.; provision of study materials or patients: B.P., M.D.S. and K.C.; data
analysis and interpretation: B.P., M.D.S. and K.C.; manuscript writing: all authors; final approval of
manuscript: all authors; accountable for all aspects of the work: all authors. All authors have read
and agreed to the published version of the manuscript.
Funding: This research is partially supported by the National Institutes of Health (NIH), National
Cancer Institute (NCI), Geographic Management of Cancer Health Disparities Programs Region 2
(GMaP R2) 3P30CA076292-24S2 (John Cleveland, PI).
Data Availability Statement: Not applicable.
Acknowledgments: Images from Biorender.com were used to create Figures 1 and 2.
Conflicts of Interest: Bruna Pellini receives research support to the institution from Bristol Myers Squibb, has received speaker honoraria from BioAscend, OncLive/MJH Life Science, and has
conducted consulting work/advisory board membership with Guidepoint, Guardant Health, and
AstraZeneca. The other authors have nothing to disclose.

References
1.

2.

3.

4.

5.
6.
7.
8.
9.
10.

11.
12.
13.
14.

15.

16.
17.
18.

Leighl, N.B.; Page, R.D.; Raymond, V.M.; Daniel, D.B.; Divers, S.G.; Reckamp, K.L.; Villalona-Calero, M.A.; Dix, D.; Odegaard, J.I.;
Lanman, R.B.; et al. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with
Newly Diagnosed Metastatic Non–small Cell Lung Cancer. Clin. Cancer Res. 2019, 25, 4691–4700. [CrossRef] [PubMed]
Aggarwal, C.; Thompson, J.C.; Black, T.A.; Katz, S.I.; Fan, R.; Yee, S.S.; Chien, A.; Evans, T.L.; Bauml, J.M.; Alley, E.W.; et al.
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung
Cancer. JAMA Oncol. 2019, 5, 173–180. [CrossRef] [PubMed]
Rolfo, C.; Mack, P.; Scagliotti, G.V.; Aggarwal, C.; Arcila, M.E.; Barlesi, F.; Bivona, T.; Diehn, M.; Dive, C.; Dziadziuszko, R.; et al.
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.
J. Thorac. Oncol. 2021, 16, 1647–1662. [CrossRef]
Forshew, T.; Murtaza, M.; Parkinson, C.; Gale, D.; Tsui, D.W.Y.; Kaper, F.; Dawson, S.-J.; Piskorz, A.M.; Jimenez-Linan, M.; Bentley,
D.; et al. Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA. Sci.
Transl. Med. 2012, 4, 136ra68. [CrossRef]
Miller, A.; Shah, R.; Pentsova, E.I.; Pourmaleki, M.; Briggs, S.; Distefano, N.; Zheng, Y.; Skakodub, A.; Mehta, S.A.; Campos,
C.; et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature 2019, 565, 654–658. [CrossRef]
Crowley, E.; Di Nicolantonio, F.; Loupakis, F.; Bardelli, A. Liquid biopsy: Monitoring cancer-genetics in the blood. Nat. Rev. Clin.
Oncol. 2013, 10, 472–484. [CrossRef] [PubMed]
Diaz, L.A., Jr.; Bardelli, A. Liquid Biopsies: Genotyping Circulating Tumor DNA. J. Clin. Oncol. 2014, 32, 579–586. [CrossRef]
Zhu, L.; Sun, H.-T.; Wang, S.; Huang, S.-L.; Zheng, Y.; Wang, C.-Q.; Hu, B.-Y.; Qin, W.; Zou, T.-T.; Fu, Y.; et al. Isolation and
characterization of exosomes for cancer research. J. Hematol. Oncol. 2020, 13, 152. [CrossRef] [PubMed]
Alix-Panabières, C.; Pantel, K. Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov. 2021, 11, 858–873. [CrossRef]
[PubMed]
Nuzzo, P.V.; Berchuck, J.E.; Korthauer, K.; Spisak, S.; Nassar, A.H.; Alaiwi, S.A.; Chakravarthy, A.; Shen, S.Y.; Bakouny, Z.;
Boccardo, F.; et al. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat. Med. 2020, 26,
1041–1043. [CrossRef] [PubMed]
Best, M.G.; Wesseling, P.; Wurdinger, T. Tumor-Educated Platelets as a Noninvasive Biomarker Source for Cancer Detection and
Progression Monitoring. Cancer Res. 2018, 78, 3407–3412. [CrossRef] [PubMed]
Mandel, P.; Metais, P. Nuclear Acids In Human Blood Plasma. Comptes Rendus Seances Soc. Biol. Ses Fil. 1948, 142, 241–243.
Corcoran, R.B.; Chabner, B.A. Application of Cell-free DNA Analysis to Cancer Treatment. N. Engl. J. Med. 2018, 379, 1754–1765.
[CrossRef] [PubMed]
Jahr, S.; Hentze, H.; Englisch, S.; Hardt, D.; Fackelmayer, F.O.; Hesch, R.D.; Knippers, R. DNA fragments in the blood plasma of
cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001, 61, 1659–1665.
[PubMed]
Wan, J.C.M.; Massie, C.; Garcia-Corbacho, J.; Mouliere, F.; Brenton, J.D.; Caldas, C.; Pacey, S.; Baird, R.; Rosenfeld, N. Liquid
biopsies come of age: Towards implementation of circulating tumour DNA. Nat. Rev. Cancer 2017, 17, 223–238. [CrossRef]
[PubMed]
Pisetsky, D.S.; Fairhurst, A.-M. The origin of extracellular DNA during the clearance of dead and dying cells. Autoimmunity 2007,
40, 281–284. [CrossRef] [PubMed]
El Messaoudi, S.; Rolet, F.; Mouliere, F.; Thierry, A.R. Circulating cell free DNA: Preanalytical considerations. Clin. Chim. Acta
2013, 424, 222–230. [CrossRef]
Kustanovich, A.; Schwartz, R.; Peretz, T.; Grinshpun, A. Life and death of circulating cell-free DNA. Cancer Biol. Ther. 2019, 20,
1057–1067. [CrossRef]

Int. J. Mol. Sci. 2022, 23, 9006

19.
20.
21.
22.
23.
24.

25.

26.

27.
28.

29.

30.
31.

32.

33.

34.
35.

36.
37.

38.
39.
40.

41.

19 of 24

Thijssen, M.A.; Swinkels, D.W.; Ruers, T.J.M.; De Kok, J.B. Difference between free circulating plasma and serum DNA in patients
with colorectal liver metastases. Anticancer Res. 2002, 22, 421–425.
Umetani, N.; Hiramatsu, S.; Hoon, D.S. Higher Amount of Free Circulating DNA in Serum than in Plasma Is Not Mainly Caused
by Contaminated Extraneous DNA during Separation. Ann. N. Y. Acad. Sci. 2006, 1075, 299–307. [CrossRef]
Siravegna, G.; Marsoni, S.; Siena, S.; Bardelli, A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol.
2017, 14, 531–548. [CrossRef]
Bettegowda, C.; Sausen, M.; Leary, R.J.; Kinde, I.; Wang, Y.; Agrawal, N.; Bartlett, B.R.; Wang, H.; Luber, B.; Alani, R.M.; et al.
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014, 6, 224. [CrossRef]
Pellini, B.; Szymanski, J.; Chin, R.-I.; Jones, P.A.; Chaudhuri, A.A. Liquid Biopsies Using Circulating Tumor DNA in Non-Small
Cell Lung Cancer. Thorac. Surg. Clin. 2020, 30, 165–177. [CrossRef] [PubMed]
Lim, C.; Tsao, M.S.; Le, L.W.; Shepherd, F.A.; Feld, R.; Burkes, R.L.; Liu, G.; Kamel-Reid, S.; Hwang, D.; Tanguay, J.; et al.
Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann. Oncol. 2015, 26,
1415–1421. [CrossRef]
U.S. Food and Drug Administration. FDA Approves First Liquid Biopsy Next-Generation Sequencing Companion Diagnostic
Test. 2020. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-nextgeneration-sequencing-companion-diagnostic-test (accessed on 23 March 2022).
U.S. Food and Drug Administration. FDA Approves Liquid Biopsy NGS Companion Diagnostic Test for Multiple Cancers and
Biomarkers. 2020. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-liquidbiopsy-ngs-companion-diagnostic-test-multiple-cancers-and-biomarkers (accessed on 23 March 2022).
Marrugo-Ramírez, J.; Mir, M.; Samitier, J. Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative
to Tissue Biopsy. Int. J. Mol. Sci. 2018, 19, 2877. [CrossRef]
Alborelli, I.; Generali, D.; Jermann, P.; Cappelletti, M.R.; Ferrero, G.; Scaggiante, B.; Bortul, M.; Zanconati, F.; Nicolet, S.; Haegele,
J.; et al. Cell-free DNA analysis in healthy individuals by next-generation sequencing: A proof of concept and technical validation
study. Cell Death Dis. 2019, 10, 534. [CrossRef]
Danesi, R.; Lo, Y.; Oellerich, M.; Beck, J.; Galbiati, S.; Del Re, M.; Lianidou, E.; Neumaier, M.; van Schaik, R. What do we need to
obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology?—Considerations on pre-analytical
aspects by the IFCC workgroup cfDNA. Clin. Chim. Acta 2021, 520, 168–171. [CrossRef]
Nikolaev, S.; Lemmens, L.; Koessler, T.; Blouin, J.-L.; Nouspikel, T. Circulating tumoral DNA: Preanalytical validation and quality
control in a diagnostic laboratory. Anal. Biochem. 2018, 542, 34–39. [CrossRef]
Parpart-Li, S.; Bartlett, B.; Popoli, M.; Adleff, V.; Tucker, L.; Steinberg, R.; Georgiadis, A.; Phallen, J.; Brahmer, J.R.; Azad, N.A.; et al.
The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA. Clin. Cancer Res. 2017, 23, 2471–2477.
[CrossRef]
Newton, C.R.; Graham, A.; Heptinstall, L.E.; Powell, S.J.; Summers, C.; Kalsheker, N.; Smith, J.C.; Markham, A.F. Analysis of any
point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989, 17, 2503–2516. [CrossRef]
[PubMed]
Malapelle, U.; Sirera, R.; Jantus-Lewintre, E.; Reclusa, P.; Calabuig, S.; Blasco, A.; Pisapia, P.; Rolfo, C.; Camps, C. Profile of
the Roche cobas®EGFR mutation test v2 for non-small cell lung cancer. Expert Rev. Mol. Diagn. 2017, 17, 209–215. [CrossRef]
[PubMed]
Vogelstein, B.; Kinzler, K.W. Digital PCR. Proc. Natl. Acad. Sci. USA 1999, 96, 9236–9241. [CrossRef] [PubMed]
Hindson, B.J.; Ness, K.D.; Masquelier, D.A.; Belgrader, P.; Heredia, N.J.; Makarewicz, A.J.; Bright, I.J.; Lucero, M.Y.; Hiddessen,
A.L.; Legler, T.C.; et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem.
2011, 83, 8604–8610. [CrossRef]
Diehl, F.; Li, M.; He, Y.; Kinzler, K.W.; Vogelstein, B.; Dressman, D. BEAMing: Single-molecule PCR on microparticles in
water-in-oil emulsions. Nat Methods 2006, 3, 551–559. [CrossRef]
Gale, D.; Plagnol, V.; Lawson, A.; Pugh, M.; Smalley, S.; Howarth, K.; Madi, M.; Durham, B.; Kumanduri, V.; Lo, K.; et al. Abstract
3639: Analytical performance and validation of an enhanced TAm-Seq circulating tumor DNA sequencing assay. Cancer Res.
2016, 76, 3639. Available online: https://aacrjournals.org/cancerres/article/76/14_Supplement/3639/611041/Abstract-3639
-Analytical-performance-and (accessed on 16 April 2022). [CrossRef]
Kinde, I.; Wu, J.; Papadopoulos, N.; Kinzler, K.W.; Vogelstein, B. Detection and quantification of rare mutations with massively
parallel sequencing. Proc. Natl. Acad. Sci. USA 2011, 108, 9530–9535. [CrossRef]
Abbosh, C.; Birkbak, N.J.; Wilson, G.A.; Jamal-Hanjani, M.; Constantin, T.; Salari, R.; Le Quesne, J.; Moore, D.A.; Veeriah, S.;
Rosenthal, R.; et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 2017, 545, 446–451. [CrossRef]
Newman, A.M.; Bratman, S.V.; To, J.; Wynne, J.F.; Eclov, N.C.W.; Modlin, L.A.; Liu, C.L.; Neal, J.W.; Wakelee, H.A.; Merritt,
R.E.; et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 2014, 20,
548–554. [CrossRef]
Newman, A.M.; Lovejoy, A.F.; Klass, D.M.; Kurtz, D.M.; Chabon, J.J.; Scherer, F.; Stehr, H.; Liu, C.L.; Bratman, S.V.; Say, C.;
et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat. Biotechnol. 2016, 34, 547–555.
[CrossRef] [PubMed]

Int. J. Mol. Sci. 2022, 23, 9006

42.
43.

44.

45.

46.

47.

48.
49.
50.

51.

52.

53.

54.
55.

56.
57.
58.
59.
60.

61.

62.
63.

64.
65.

20 of 24

Phallen, J.; Sausen, M.; Adleff, V.; Leal, A.; Hruban, C.; White, J.; Anagnostou, V.; Fiksel, J.; Cristiano, S.; Papp, E.; et al. Direct
detection of early-stage cancers using circulating tumor DNA. Sci. Transl. Med. 2017, 9, 1252–1255. [CrossRef]
Lanman, R.B.; Mortimer, S.A.; Zill, O.A.; Sebisanovic, D.; Lopez, R.; Blau, S.; Collisson, E.A.; Divers, S.G.; Hoon, D.; Kopetz,
S.; et al. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free
Circulating Tumor DNA. PLoS ONE 2015, 10, e0140712. [CrossRef]
Odegaard, J.I.; Vincent, J.J.; Mortimer, S.; Vowles, J.V.; Ulrich, B.C.; Banks, K.C.; Fairclough, S.R.; Zill, O.A.; Sikora, M.; Mokhtari,
R.; et al. Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based
Methodologies. Clin. Cancer Res. 2018, 24, 3539–3549. [CrossRef]
Lee, J.K.; Hazar-Rethinam, M.; Decker, B.; Gjoerup, O.; Madison, R.W.; Lieber, D.S.; Chung, J.H.; Schrock, A.B.; Creeden, J.;
Venstrom, J.M.; et al. The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. Clin. Cancer Res. 2022,
28, 728–737. [CrossRef] [PubMed]
Murtaza, M.; Dawson, S.-J.; Tsui, D.W.Y.; Gale, D.; Forshew, T.; Piskorz, A.M.; Parkinson, C.; Chin, S.-F.; Kingsbury, Z.; Wong,
A.S.C.; et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497,
108–112. [CrossRef]
Chan, K.A.; Jiang, P.; Zheng, Y.W.; Liao, G.J.; Sun, H.; Wong, J.; Siu, S.S.N.; Chan, W.C.; Chan, S.L.; Chan, A.T.; et al. Cancer
Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and
Tumoral Heterogeneity by Massively Parallel Sequencing. Clin. Chem. 2013, 59, 211–224. [CrossRef]
Welch, J.S. Use of Whole-Genome Sequencing to Diagnose a Cryptic Fusion Oncogene. JAMA 2011, 305, 1577–1584. [CrossRef]
Shen, S.Y.; Burgener, J.M.; Bratman, S.V.; De Carvalho, D.D. Preparation of cfMeDIP-seq libraries for methylome profiling of
plasma cell-free DNA. Nat. Protoc. 2019, 14, 2749–2780. [CrossRef]
Huang, J.; Soupir, A.C.; Schlick, B.D.; Teng, M.; Sahin, I.H.; Permuth, J.B.; Siegel, E.M.; Manley, B.J.; Pellini, B.; Wang, L. Cancer
Detection and Classification by CpG Island Hypermethylation Signatures in Plasma Cell-Free DNA. Cancers 2021, 13, 5611.
[CrossRef]
Klein, E.; Richards, D.; Cohn, A.; Tummala, M.; Lapham, R.; Cosgrove, D.; Chung, G.; Clement, J.; Gao, J.; Hunkapiller, N.; et al.
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann.
Oncol. 2021, 32, 1167–1177. [CrossRef]
Mathios, D.; Johansen, J.S.; Cristiano, S.; Medina, J.E.; Phallen, J.; Larsen, K.R.; Bruhm, D.C.; Niknafs, N.; Ferreira, L.; Adleff,
V.; et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat. Commun. 2021, 12, 5060.
[CrossRef]
Przybyl, J.; Chabon, J.J.; Spans, L.; Ganjoo, K.N.; Vennam, S.; Newman, A.M.; Forgó, E.; Varma, S.; Zhu, S.; Debiec-Rychter,
M.; et al. Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma.
Clin. Cancer Res. 2018, 24, 2688–2699. [CrossRef]
Cohen, J.D.; Li, L.; Wang, Y.; Thoburn, C.; Afsari, B.; Danilova, L.; Douville, C.; Javed, A.A.; Wong, F.; Mattox, A.; et al. Detection
and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018, 359, 926–930. [CrossRef]
Chin, R.-I.; Chen, K.; Usmani, A.; Chua, C.; Harris, P.K.; Binkley, M.S.; Azad, T.D.; Dudley, J.C.; Chaudhuri, A.A. Detection of
Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). Mol. Diagn. Ther. 2019, 23, 311–331.
[CrossRef]
Herbst, R.S.; Morgensztern, D.; Boshoff, C. The biology and management of non-small cell lung cancer. Nature 2018, 553, 446–454.
[CrossRef]
Shields, M.D.; Marin-Acevedo, J.A.; Pellini, B. Immunotherapy for Advanced Non–Small Cell Lung Cancer: A Decade of Progress.
Am. Soc. Clin. Oncol. Educ. Book 2021, 41, e105–e127. [CrossRef]
Schiller, J.H.; Harrington, D.; Belani, C.P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D.H. Comparison of Four
Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2002, 346, 92–98. [CrossRef]
Yamamoto, N.; Nambu, Y.; Fujimoto, T.; Koshiji, M. A Landmark Point Analysis with Cytotoxic Agents for Advanced NSCLC.
J. Thorac. Oncol. 2009, 4, 697–701. [CrossRef]
Zhou, C.; Wu, Y.-L.; Chen, G.; Feng, J.; Liu, X.-Q.; Wang, C.; Zhang, S.; Wang, J.; Zhou, S.; Ren, S.; et al. Erlotinib versus
chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011, 12, 735–742. [CrossRef]
Mok, T.S.; Wu, Y.-L.; Ahn, M.-J.; Garassino, M.C.; Kim, H.R.; Ramalingam, S.S.; Shepherd, F.A.; He, Y.; Akamatsu, H.; Theelen,
W.S.; et al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer. N. Engl. J. Med. 2017, 376, 629–640.
[CrossRef]
Shaw, A.T.; Kim, D.-W.; Nakagawa, K.; Seto, T.; Crinó, L.; Ahn, M.-J.; De Pas, T.; Besse, B.; Solomon, B.J.; Blackhall, F.; et al.
Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer. N. Engl. J. Med. 2013, 368, 2385–2394. [CrossRef]
Mok, T.S.; Wu, Y.L.; Yu, C.J.; Zhou, C.; Chen, Y.M.; Zhang, L.; Ignacio, J.; Liao, M.; Srimuninnimit, V.; Boyer, M.J.; et al.
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced
non-small-cell lung cancer. J. Clin. Oncol. 2009, 27, 5080–5087. [CrossRef]
Hong, D.S.; Fakih, M.G.; Strickler, J.H.; Desai, J.; Durm, G.A.; Shapiro, G.I.; Falchook, G.S.; Price, T.J.; Sacher, A.; Denlinger,
C.S.; et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N. Engl. J. Med. 2020, 383, 1207–1217. [CrossRef]
Shaw, A.T.; Solomon, B.J. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 2015, 372, 683–684. [CrossRef]

Int. J. Mol. Sci. 2022, 23, 9006

66.
67.
68.
69.
70.
71.

72.

73.

74.

75.

76.

77.
78.
79.
80.
81.

82.
83.
84.

85.

86.

21 of 24

Brown, N.A.; Aisner, D.L.; Oxnard, G.R. Precision Medicine in Non–Small Cell Lung Cancer: Current Standards in Pathology and
Biomarker Interpretation. Am. Soc. Clin. Oncol. Educ. Book 2018, 38, 708–715. [CrossRef] [PubMed]
Schwartzberg, L.; Kim, E.S.; Liu, D.; Schrag, D. Precision Oncology: Who, How, What, When, and When Not? Am. Soc. Clin.
Oncol. Educ. Book 2017, 160–169. [CrossRef] [PubMed]
Bratman, S.; Newman, A.; Alizadeh, A.A.; Diehn, M. Potential clinical utility of ultrasensitive circulating tumor DNA detection
with CAPP-Seq. Expert Rev. Mol. Diagn. 2015, 15, 715–719. [CrossRef]
Elazezy, M.; Joosse, S.A. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management.
Comput. Struct. Biotechnol. J. 2018, 16, 370–378. [CrossRef]
Huggett, J.F.; Whale, A. Digital PCR as a Novel Technology and Its Potential Implications for Molecular Diagnostics. Clin. Chem.
2013, 59, 1691–1693. [CrossRef] [PubMed]
Oxnard, G.R.; Paweletz, C.P.; Kuang, Y.; Mach, S.L.; O’Connell, A.; Messineo, M.M.; Luke, J.J.; Butaney, M.; Kirschmeier, P.;
Jackman, D.M.; et al. Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative
Next-Generation Genotyping of Cell-Free Plasma DNA. Clin. Cancer Res. 2014, 20, 1698–1705. [CrossRef] [PubMed]
Leary, R.J.; Sausen, M.; Kinde, I.; Papadopoulos, N.; Carpten, J.D.; Craig, D.; O’Shaughnessy, J.; Kinzler, K.W.; Parmigiani, G.;
Vogelstein, B.; et al. Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing.
Sci. Transl. Med. 2012, 4, 162ra154. [CrossRef] [PubMed]
Narayan, A.; Carriero, N.J.; Gettinger, S.N.; Kluytenaar, J.; Kozak, K.R.; Yock, T.I.; Muscato, N.E.; Ugarelli, P.; Decker, R.H.; Patel,
A.A. Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-Suppressed Multiplexed Deep
Sequencing. Cancer Res. 2012, 72, 3492–3498. [CrossRef] [PubMed]
Paweletz, C.P.; Sacher, A.G.; Raymond, C.K.; Alden, R.S.; O’Connell, A.; Mach, S.L.; Kuang, Y.; Gandhi, L.; Kirschmeier, P.; English,
J.M.; et al. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in
Cell-Free DNA from Advanced Lung Cancer Patients. Clin. Cancer Res. 2016, 22, 915–922. [CrossRef]
Chabon, J.J.; Simmons, A.D.; Lovejoy, A.F.; Esfahani, M.S.; Newman, A.M.; Haringsma, H.J.; Kurtz, D.M.; Stehr, H.; Scherer, F.;
Karlovich, C.A.; et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung
cancer patients. Nat. Commun. 2016, 7, 11815. [CrossRef] [PubMed]
Lin, J.J.; Ritterhouse, L.L.; Ali, S.M.; Bailey, M.; Schrock, A.B.; Gainor, J.F.; Ferris, L.A.; Mino-Kenudson, M.; Miller, V.A.; Iafrate,
A.J.; et al. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer. J. Thorac. Oncol. 2017, 12,
872–877. [CrossRef]
Sholl, L.M.; Sun, H.; Butaney, M.; Zhang, C.; Lee, C.; Jänne, P.A.; Rodig, S.J. ROS1 Immunohistochemistry for Detection of
ROS1-Rearranged Lung Adenocarcinomas. Am. J. Surg. Pathol. 2013, 37, 1441–1449. [CrossRef]
Zheng, Z.; Liebers, M.; Zhelyazkova, B.; Cao, Y.; Panditi, D.; Lynch, K.D.; Chen, J.; Robinson, H.E.; Shim, H.S.; Chmielecki, J.; et al.
Anchored multiplex PCR for targeted next-generation sequencing. Nat. Med. 2014, 20, 1479–1484. [CrossRef] [PubMed]
Dagogo-Jack, I.; Rooney, M.; Nagy, R.J.; Lin, J.J.; Chin, E.; Ferris, L.A.; Ackil, J.; Lennerz, J.K.; Lanman, R.B.; Gainor, J.F.; et al.
Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. J. Thorac. Oncol. 2019, 14, 816–824. [CrossRef] [PubMed]
FoundationOne®CDx. 2022. Available online: https://www.foundationmedicine.com/test/foundationone-liquid-cdx (accessed
on 12 June 2022).
Li, M.; Hou, X.; Zheng, L.; Ma, Y.; Li, D.; Lv, Y.; Chen, J.; Zheng, W.; Shao, Y.; Mou, Y.; et al. Utilizing phenotypic characteristics of
metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell
lung cancer patients: Development and validation of a prediction model in a prospective cohort study. ESMO Open 2022,
7, 100305.
Sudhindra, A.; Ochoa, R.; Santos, E.S. Biomarkers, prediction, and prognosis in non-small-cell lung cancer: A platform for
personalized treatment. Clin. Lung Cancer 2011, 12, 360–368. [CrossRef]
Wei, L.; Wu, W.; Han, L.; Yu, W.; Du, Y. A quantitative analysis of the potential biomarkers of non-small cell lung cancer by
circulating cell-free DNA. Oncol. Lett. 2018, 16, 4353–4360.
Normanno, N.; Rachiglio, A.M.; Roma, C.; Fenizia, F.; Esposito, C.; Pasquale, R.; La Porta, M.L.; Iannaccone, A.; Micheli, F.;
Santangelo, M.; et al. Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities. J. Cell.
Biochem. 2012, 114, 514–524. [CrossRef]
Dagogo-Jack, I.; Fabrizio, D.; Lennerz, J.; Schrock, A.B.; Young, L.; Mino-Kenudson, M.; Digumarthy, S.R.; Heist, R.S.; Ali, S.M.;
Miller, V.A.; et al. Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a
Patient with Advanced MET-Amplified Lung Adenocarcinoma. J. Thorac. Oncol. 2017, 12, e155–e157. [CrossRef] [PubMed]
Wu, Y.-L.; Lee, J.S.; Thongprasert, S.; Yu, C.-J.; Zhang, L.; Ladrera, G.; Srimuninnimit, V.; Sriuranpong, V.; Sandoval-Tan, J.; Zhu,
Y.; et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer
(FASTACT-2): A randomised, double-blind trial. Lancet Oncol. 2013, 14, 777–786. [CrossRef]

Int. J. Mol. Sci. 2022, 23, 9006

87.

88.

89.

90.

91.

92.

93.
94.
95.
96.
97.

98.

99.
100.

101.
102.

103.

104.
105.

106.
107.

108.

22 of 24

Mok, T.; Wu, Y.-L.; Lee, J.S.; Yu, C.-J.; Sriuranpong, V.; Sandoval-Tan, J.; Ladrera, G.; Thongprasert, S.; Srimuninnimit, V.; Liao,
M.; et al. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes
in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clin. Cancer Res. 2015, 21, 3196–3203.
[CrossRef] [PubMed]
Phallen, J.; Leal, A.; Woodward, B.D.; Forde, P.M.; Naidoo, J.; Marrone, K.A.; Brahmer, J.R.; Fiksel, J.; Medina, J.E.; Cristiano,
S.; et al. Early Noninvasive Detection of Response to Targeted Therapy in Non–Small Cell Lung Cancer. Cancer Res. 2019, 79,
1204–1213. [CrossRef] [PubMed]
Serrano, C.; Leal, A.; Kuang, Y.; Morgan, J.A.; Barysauskas, C.M.; Phallen, J.; Triplett, O.; Mariño-Enríquez, A.; Wagner, A.J.;
Demetri, G.D.; et al. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase
Inhibitor Refractory Gastrointestinal Stromal Tumors. Clin. Cancer Res. 2019, 25, 7287–7293. [CrossRef]
Garrido, P.; Paz-Ares, L.; Majem, M.; Morán, T.; Trigo, J.M.; Bosch-Barrera, J.; Garcίa-Campelo, R.; González-Larriba, J.L.;
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